Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice

Biochemical and Biophysical Research Communications

Volumn 490, Issue 3, 2017, Pages 841-848

  Liu, Hsuan Miao ^a   Liao, Jyh Fei ^a   Lee, Tzung Yan ^b,c,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Farnesoid X receptor; GW4064; Inflammatory bowel disease; Mitochondrial dysfunction; Toll like receptor 4

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; CRYOPYRIN; FARNESOID X RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE; MYD88 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; GENE EXPRESSION; ILEOCOLITIS; ILEUM; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIGHT JUNCTION; AGONISTS; ANIMAL; C57BL MOUSE; COLON; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; KNOCKOUT MOUSE; MITOCHONDRION; PATHOLOGY;

ANIMALS; COLON; ILEUM; INFLAMMATORY BOWEL DISEASES; ISOXAZOLES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TOLL-LIKE RECEPTOR 4;

EID: 85021199279     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.06.129     Document Type: Article

References (29)

1. Kaplan, G.G., The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 720–727.
2. Roberts-Thomson, I.C., Fon, J., Uylaki, W., et al. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert. Rev. Gastroenterol. Hepatol. 5 (2011), 703–716.
3. Zhao, H., Anand, A.R., Ganju, R.K., Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inflammation and its expression is dysregulated during endotoxemia. J. Immunol. 192 (2014), 385–393.
4. Hausmann, M., Kiessling, S., Mestermann, S., et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122 (2002), 1987–2000.
5. Lee, S.H., Starkey, P.M., Gordon, S., Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J. Exp. Med. 161 (1985), 475–489.
6. Sanchez-Munoz, F., Dominguez-Lopez, A., Yamamoto-Furusho, J.K., Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 14 (2008), 4280–4288.
7. Monteleone, G., Kumberova, A., Croft, N.M., et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108 (2001), 601–609.
8. Schoultz, I., Verma, D., Halfvarsson, J., et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am. J. Gastroenterol. 104 (2009), 1180–1188.
9. Bauer, C., Duewell, P., Mayer, C., et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59 (2010), 1192–1199.
10. Bauer, C., Duewell, P., Lehr, H.A., et al. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig. Dis. 30:Suppl 1 (2012), 82–90.
11. Nakahira, K., Haspel, J.A., Rathinam, V.A., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12 (2011), 222–230.
12. Beltran, B., Nos, P., Dasi, F., et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. Inflamm. Bowel Dis. 16 (2010), 76–86.
13. Restivo, N.L., Srivastava, M.D., Schafer, I.A., et al. Mitochondrial dysfunction in a patient with crohn disease: possible role in pathogenesis. J. Pediatr. Gastroenterol. Nutr. 38 (2004), 534–538.
14. Nazli, A., Yang, P.C., Jury, J., et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am. J. Pathol. 164 (2004), 947–957.
15. Attinkara, R., Mwinyi, J., Truninger, K., et al. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res. Notes, 5, 2012, 461.
16. Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
17. Walters, J.R., Johnston, I.M., Nolan, J.D., et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment. Pharmacol. Ther. 41 (2015), 54–64.
18. Inagaki, T., Moschetta, A., Lee, Y.K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3920–3925.
19. Ito, S., Tanaka, Y., Oshino, R., et al. GADD34 suppresses lipopolysaccharide-induced sepsis and tissue injury through the regulation of macrophage activation. Cell. Death Dis., 7, 2016, e2219.
20. Mencarelli, A., Cipriani, S., Renga, B., et al. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity. Nutr. Metab. Cardiovasc. Dis. 23 (2013), 94–101.
21. Turner, J.R., Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9 (2009), 799–809.
22. Guo, S., Nighot, M., Al-Sadi, R., et al. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J. Immunol. 195 (2015), 4999–5010.
23. Novak, E.A., Mollen, K.P., Mitochondrial dysfunction in inflammatory bowel disease. Front. Cell. Dev. Biol., 3, 2015, 62.
24. Szendroedi, J., Phielix, E., Roden, M., The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8 (2011), 92–103.
25. Szanto, I., Rubbia-Brandt, L., Kiss, P., Steger, K., et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J. Pathol. 207 (2005), 164–176.
26. Kawahara, T., Kohjima, M., Kuwano, Y., et al. Helicobacter pylori lipopolysaccharide activates Rac1 and transcription of NADPH oxidase Nox1 and its organizer NOXO1 in Guinea pig gastric mucosal cells. Am. J. Physiol. Cell. Physiol. 288 (2005), C450–C457.
27. Lassegue, B., San Martin, A., Griendling, K.K., Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ. Res. 110 (2012), 1364–1390.
28. Shimada, K., Crother, T.R., Karlin, J., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36 (2012), 401–414.
29. Aguilera, M., Darby, T., Melgar, S., The complex role of inflammasomes in the pathogenesis of Inflammatory Bowel Diseases - lessons learned from experimental models. Cytokine Growth Factor Rev. 25 (2014), 715–730.